Matthew Hotopf
Auto-generated profile, based on publicly available information

Matthew Hotopf

Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in The Lancet Psychiatry
Verified
Journal Article
Closed access
EHEmily A Holmes
Emily A Holmes
RORory C O'COnnor
Rory C O'COnnor
VPV Hugh Perry
V Hugh Perry
ITIrene Tracey
Irene Tracey
SWSimon Wessely
Simon Wessely
EBEd Bullmore
Ed Bullmore

3 September 2013 in Rheumatology
Verified
Journal Article
Open access
PDF file
FMFaith Matcham
Faith Matcham
LRLauren Rayner
Lauren Rayner
SSSophia Steer
Sophia Steer
MHMatthew Hotopf
Matthew Hotopf
Objective. There is substantial uncertainty regarding the prevalence of depression in RA. We conducted a systematic review aiming to describe the prevalence of depression in RA. Methods. Web of Science, PsycINFO, CINAHL, Embase, Medline and PubMed were searched for cross-sectional studies reporting a prevalence estimate for depression in adult RA patients. Studies were reviewed in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines and a meta-analysis was performed. Results. A total of 72 studies, including 13 189 patients, were eligible for inclusion in the review. Forty-three methods of defining depression were reported. Meta-analyses revealed the prevalence of major depressive disorder to be 16.8% (95% CI 10%, 24%). According to the PHQ-9, the prevalence of depression was 38.8% (95% CI 34%, 43%), and prevalence levels according to the HADS with thresholds of 8 and 11 were 34.2% (95% CI 25%, 44%) and 14.8% (95% CI 12%, 18%), respectively. The main influence on depression prevalence was the mean age of the sample. Conclusion. Depression is highly prevalent in RA and associated with poorer RA outcomes. This suggests that optimal care of RA patients may include the detection and management of depression.

18 May 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CCChin-Kuo Chang
Chin-Kuo Chang
RHRichard D. Hayes
Richard D. Hayes
GPGayan Perera
Gayan Perera
MBMathew T. M. Broadbent
Mathew T. M. Broadbent
AFAndrea C. Fernandes
Andrea C. Fernandes
RSRobert Stewart
Robert Stewart
Despite improving healthcare, the gap in mortality between people with serious mental illness (SMI) and general population persists, especially for younger age groups. The electronic database from a large and comprehensive secondary mental healthcare provider in London was utilized to assess the impact of SMI diagnoses on life expectancy at birth. People who were diagnosed with SMI (schizophrenia, schizoaffective disorder, bipolar disorder), substance use disorder, and depressive episode/disorder before the end of 2009 and under active review by the South London and Maudsley NHS Foundation Trust (SLAM) in southeast London during 2007–09 comprised the sample, retrieved by the SLAM Case Register Interactive Search (CRIS) system. We estimated life expectancy at birth for people with SMI and each diagnosis, from national mortality returns between 2007–09, using a life table method. A total of 31,719 eligible people, aged 15 years or older, with SMI were analyzed. Among them, 1,370 died during 2007–09. Compared to national figures, all disorders were associated with substantially lower life expectancy: 8.0 to 14.6 life years lost for men and 9.8 to 17.5 life years lost for women. Highest reductions were found for men with schizophrenia (14.6 years lost) and women with schizoaffective disorders (17.5 years lost). The impact of serious mental illness on life expectancy is marked and generally higher than similarly calculated impacts of well-recognised adverse exposures such as smoking, diabetes and obesity. Strategies to identify and prevent causes of premature death are urgently required.

1 October 2014 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Open access
FMFaith Matcham
Faith Matcham
ISIan C. Scott
Ian C. Scott
LRLauren Rayner
Lauren Rayner
MHMatthew Hotopf
Matthew Hotopf
GKGabrielle H. Kingsley
Gabrielle H. Kingsley
SSSophia Steer
Sophia Steer
The assessment of health-related quality-of-life (HRQoL) in rheumatoid arthritis (RA) is becoming increasingly common in both research and clinical practice. One of the most widely used tools for measuring HRQoL is the Medical Outcomes Study 36-item Short-Form Health Survey (SF-36). We conducted a systematic review examining the impact of RA on HRQoL, measured through the SF-36. MEDLINE and Embase were searched for observational studies reporting mean and standard deviation scores for each domain of the SF-36 in adult RA patients. Studies were reviewed in accordance with PRISMA guidelines, and a random-effects meta-analysis was performed. In total, 31 studies were eligible for inclusion in the meta-analysis, including 22,335 patients. Meta-analyses found that pooled mean HRQoL score for the SF-36 physical component summary was 34.1 (95% CI: 22.0-46.1) and mental component summary was 45.6 (95% CI: 30.3-60.8). Increased age was associated with reduced physical function and physical component summary (PCS) scores but improved mental health and mental component summary (MCS) scores. Female gender was associated with improved scores on role physical, bodily pain and PCS but reduced mental health and MCS scores. Longer disease duration was associated with improved MCS. Patients with RA have a substantially reduced HRQoL in comparison to both other physical illnesses and in comparison to normative datasets from UK and USA populations. RA has a substantial impact on HRQoL. This supports recent NICE guidelines stipulating that RA patients should be regularly assessed for the impact their disease has on HRQoL and appropriate management provided.

1 May 2010 in The Lancet
Verified
Journal Article
Closed access
NFNicola T Fear
Nicola T Fear
MJMargaret Jones
Margaret Jones
DMDominic Murphy
Dominic Murphy
LHLisa Hull
Lisa Hull
AIAmy C Iversen
Amy C Iversen
SWSimon Wessely
Simon Wessely

12 August 2009 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
RSRobert Stewart
Robert Stewart
MSMishael Soremekun
Mishael Soremekun
GPGayan Perera
Gayan Perera
MBMatthew Broadbent
Matthew Broadbent
FCFelicity Callard
Felicity Callard
SLSimon Lovestone
Simon Lovestone
Case registers have been used extensively in mental health research. Recent developments in electronic medical records, and in computer software to search and analyse these in anonymised format, have the potential to revolutionise this research tool. We describe the development of the South London and Maudsley NHS Foundation Trust (SLAM) Biomedical Research Centre (BRC) Case Register Interactive Search tool (CRIS) which allows research-accessible datasets to be derived from SLAM, the largest provider of secondary mental healthcare in Europe. All clinical data, including free text, are available for analysis in the form of anonymised datasets. Development involved both the building of the system and setting in place the necessary security (with both functional and procedural elements). Descriptive data are presented for the Register database as of October 2008. The database at that point included 122,440 cases, 35,396 of whom were receiving active case management under the Care Programme Approach. In terms of gender and ethnicity, the database was reasonably representative of the source population. The most common assigned primary diagnoses were within the ICD mood disorders (n = 12,756) category followed by schizophrenia and related disorders (8158), substance misuse (7749), neuroses (7105) and organic disorders (6414). The SLAM BRC Case Register represents a 'new generation' of this research design, built on a long-running system of fully electronic clinical records and allowing in-depth secondary analysis of both numerical, string and free text data, whilst preserving anonymity through technical and procedural safeguards.